Protocol Ledger

NCT05490446 · Phase II · ACTIVE NOT RECRUITING

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Interventional Phase II clinical trial protocol NCT05490446 sponsored by Agios Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-07 Enrollment: 87 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05490446
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)87 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05490446
Protocol FieldVerified Registry Value
NCT IdentifierNCT05490446
Consolidated Lead SponsorAgios Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment87 participants (ACTUAL)
Registered Start Date2022-11-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI